CancerNetwork® sat down with Edmund Qiao at the 2021 American Society of Clinical Oncology Annual Meeting to talk about prostate-specific antigen screening and prostate cancer prevention in African American men.
At the 2021 American Society of Clinical Oncology Annual Meeting, CancerNetwork® spoke with Edmund Qiao, a fourth-year medical student from University of California San Diego and lead author of a study about prostate cancer prevention in African American men.
Given that African American men are more likely to be diagnosed with lethal prostate cancer at a younger age compared to non-Hispanic White men, the study aimed to determine interventional measures that may combat health disparities in this population. The study encompassed over 4000 men with a median age of 51.8 years and showed that increased intensity of prostate-specific antigen screening led to earlier detection and potential improvement in outcomes for younger African American men.
Transcript:
This study emphasizes the importance of primary prevention of prostate cancer. We focus on the prostate-specific antigen screening for the basis of the presentation. One fact of our models is that we do include [primary care provider (PCP)]–utilization rates as well, [which is] basically a measure of how frequently a patient goes to the PCP. We did find that those were also significantly associated with a reduced risk of all of our end points. Taking [that] into context with the PSA screening, we feel that primary prevention of prostate cancer comes through primary care visits and just continuity of care. In terms of where [to] start, the primary prevention of prostate cancer is a very important aspect of the overall care.
References
Qiao E, Kotha N, Nalawade V, et al. Association of increased intensity of prostate-specific antigen screening in younger African American men with improved prostate cancer outcomes. J Clin Oncol. 2021;39(suppl 15):5004. doi: 10.1200/JCO.2021.39.15_suppl.5004
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.